Table 2.
Therapy beyond the 18-month trial period for patients in the CYCAZAREM trial
| Time after Randomization (mo) | Cyclophosphamide | Other Immunosuppressantsa | Prednisolone | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CYC | AZA | P Value | CYC | AZA | P Value | CYC | AZA | P Value | |
| 19–24 | 9 (17) | 6 (11) | 0.58 | 37 (68) | 36 (69) | >0.99 | 47 (81) | 46 (82) | 0.99 |
| 25–36 | 4 (8) | 6 (12) | 0.74 | 28 (56) | 30 (64) | 0.53 | 35 (65) | 40 (77) | 0.20 |
| 37–48 | 2 (4) | 4 (8) | 0.68 | 23 (47) | 28 (59) | 0.23 | 28 (53) | 31 (61) | 0.43 |
| 49–60 | 1 (2) | 4 (8) | 0.36 | 20 (43) | 27 (60) | 0.14 | 21 (42) | 28 (56) | 0.23 |
Data are presented as n (%). During all time intervals, patients with missing data were excluded from analysis. P values were obtained by Fisher’s exact test. CYCAZAREM, Cyclophosphamide versus Azathioprine for Early Remission Phase of Vasculitis.
a
Azathioprine, methotrexate, tacrolimus, gusperimus, dapsone, infliximab, and/or mycophenolate mofetil.